O	0	1	A
O	2	13	multicentre
O	13	14	,
O	15	25	randomized
O	26	31	pilot
O	32	37	trial
O	38	47	comparing
B-intervention	48	56	vascular
I-intervention	57	63	access
I-intervention	64	74	strategies
O	75	78	for
O	79	84	early
O	85	90	stage
O	91	97	breast
O	98	104	cancer
O	105	113	patients
O	114	123	receiving
O	124	127	non
O	127	128	-
O	128	139	trastuzumab
O	140	150	containing
O	151	163	chemotherapy
O	163	164	.

O	165	168	All
O	169	177	vascular
O	178	184	access
O	185	195	strategies
O	196	212	foradministering
O	213	225	chemotherapy
O	226	228	in
O	229	234	early
O	235	240	stage
O	241	247	breast
O	248	254	cancer
O	255	256	(
O	256	259	EBC
O	259	260	)
O	261	264	are
O	265	275	associated
O	276	280	with
O	281	286	risks
O	287	290	and
O	291	299	benefits
O	299	300	.

O	301	303	As
O	304	307	the
O	308	312	most
O	313	322	effective
O	323	327	type
O	328	330	of
O	331	337	access
O	338	340	is
O	341	348	unknown
O	349	350	a
O	351	362	feasibility
O	363	368	trial
O	368	369	,
O	370	375	prior
O	376	378	to
O	379	389	conducting
O	390	391	a
O	392	397	large
O	398	407	pragmatic
O	408	413	trial
O	413	414	,
O	415	418	was
O	419	429	undertaken
O	429	430	.

O	431	434	The
O	435	440	trial
O	441	452	methodology
O	453	461	utilized
O	462	467	broad
O	468	479	eligibility
O	480	488	criteria
O	489	492	and
O	493	496	the
O	497	507	integrated
O	508	515	consent
O	516	521	model
O	522	535	incorporating
O	536	540	oral
O	541	548	consent
O	548	549	.

B-eligibility	550	553	EBC
I-eligibility	554	562	patients
I-eligibility	563	572	receiving
I-eligibility	573	576	non
I-eligibility	576	577	-
I-eligibility	577	588	trastuzumab
I-eligibility	588	589	-
I-eligibility	589	599	containing
I-eligibility	600	612	chemotherapy
O	613	617	were
O	618	628	randomized
O	629	631	to
O	632	642	peripheral
O	643	649	access
O	650	652	or
B-control	653	660	central
I-control	661	665	line
I-control	666	675	insertion
O	675	676	.

O	677	680	The
O	681	682	a
O	683	689	priori
O	690	700	definition
O	701	703	of
O	704	715	feasibility
O	716	719	was
O	719	720	:
O	721	722	>
O	723	725	25
O	725	726	%
O	727	729	of
O	730	738	patients
O	739	749	approached
O	750	756	agreed
O	757	759	to
O	760	773	randomisation
O	774	777	and
O	778	779	>
O	780	782	25
O	782	783	%
O	784	786	of
O	787	797	physicians
O	798	808	approached
O	809	817	patients
O	817	818	.

O	819	828	Secondary
O	829	837	outcomes
O	838	846	included
B-outcome-Measure	847	852	rates
I-outcome-Measure	853	855	of
I-outcome-Measure	856	860	line
I-outcome-Measure	860	861	-
I-outcome-Measure	861	871	associated
I-outcome-Measure	872	885	complications
O	885	886	.

O	887	889	Of
B-total-participants	890	893	159
O	894	902	patients
O	903	913	approached
O	913	914	,
B-total-participants	915	918	150
O	919	920	(
O	920	922	94
O	922	923	.
O	923	924	3
O	924	925	%
O	925	926	)
O	927	933	agreed
O	934	936	to
O	937	950	randomisation
O	950	951	,
B-intervention-participants	952	954	77
O	955	956	(
O	956	958	51
O	958	959	.
O	959	960	3
O	960	961	%
O	961	962	)
O	963	967	were
O	968	978	randomized
O	979	981	to
O	982	992	peripheral
O	993	996	and
B-control-participants	997	999	73
O	1000	1001	(
O	1001	1003	48
O	1003	1004	.
O	1004	1005	7
O	1005	1006	%
O	1006	1007	)
O	1008	1010	to
O	1011	1018	central
O	1019	1025	access
O	1025	1026	.

O	1027	1028	6
O	1028	1029	/
O	1029	1031	26
O	1032	1033	(
O	1033	1035	23
O	1035	1036	.
O	1036	1037	1
O	1037	1038	%
O	1038	1039	)
O	1040	1042	of
O	1043	1050	medical
O	1051	1062	oncologists
O	1063	1073	approached
O	1074	1082	patients
O	1082	1083	.

B-outcome	1084	1089	Rates
I-outcome	1090	1092	of
I-outcome	1093	1106	complications
O	1107	1110	per
O	1111	1123	chemotherapy
O	1124	1130	cycles
O	1131	1133	in
O	1134	1137	the
O	1138	1148	peripheral
O	1149	1151	vs
O	1152	1159	central
O	1160	1166	access
O	1167	1173	groups
O	1174	1178	with
O	1179	1183	risk
O	1184	1194	difference
O	1195	1196	(
O	1196	1198	RD
O	1198	1199	)
O	1200	1201	(
O	1201	1203	95
O	1203	1204	%
O	1205	1207	CI
O	1207	1208	)
O	1209	1213	were
O	1213	1214	:
B-outcome	1215	1225	thrombotic
I-outcome	1226	1232	events
I-outcome	1233	1242	requiring
I-outcome	1243	1258	anticoagulation
O	1259	1260	[
B-iv-bin-abs	1260	1261	1
O	1262	1263	(
B-iv-bin-percent	1263	1264	0
I-iv-bin-percent	1264	1265	.
I-iv-bin-percent	1265	1266	3
I-iv-bin-percent	1266	1267	%
O	1267	1268	)
O	1269	1271	vs
O	1271	1272	.
B-cv-bin-abs	1273	1274	3
O	1275	1276	(
B-cv-bin-percent	1276	1277	1
I-cv-bin-percent	1277	1278	.
I-cv-bin-percent	1278	1279	0
I-cv-bin-percent	1279	1280	%
O	1280	1281	)
O	1281	1282	,
O	1283	1285	RD
O	1286	1287	-
O	1288	1289	0
O	1289	1290	.
O	1290	1291	7
O	1291	1292	(
O	1292	1293	-
O	1294	1295	1
O	1295	1296	.
O	1296	1297	9
O	1297	1298	,
O	1298	1299	0
O	1299	1300	.
O	1300	1301	5
O	1301	1302	)
O	1302	1303	]
O	1303	1304	,
B-outcome	1305	1309	line
I-outcome	1310	1320	infections
O	1321	1322	[
B-iv-bin-abs	1322	1323	0
O	1324	1325	(
B-iv-bin-percent	1325	1326	0
I-iv-bin-percent	1326	1327	%
O	1327	1328	)
O	1329	1331	vs
O	1331	1332	.
B-cv-bin-abs	1333	1334	1
O	1335	1336	(
B-cv-bin-percent	1336	1337	0
I-cv-bin-percent	1337	1338	.
I-cv-bin-percent	1338	1339	3
I-cv-bin-percent	1339	1340	%
O	1340	1341	)
O	1341	1342	,
O	1343	1345	RD
O	1346	1347	-
O	1348	1349	0
O	1349	1350	.
O	1350	1351	3
O	1351	1352	(
O	1352	1353	-
O	1354	1355	0
O	1355	1356	.
O	1356	1357	9
O	1357	1358	,
O	1358	1359	0
O	1359	1360	.
O	1360	1361	3
O	1361	1362	)
O	1362	1363	]
O	1363	1364	,
B-outcome	1365	1374	phlebitis
O	1375	1376	[
B-iv-bin-abs	1376	1377	2
O	1378	1379	(
B-iv-bin-percent	1379	1380	0
I-iv-bin-percent	1380	1381	.
I-iv-bin-percent	1381	1382	6
I-iv-bin-percent	1382	1383	%
O	1383	1384	)
O	1385	1387	vs
O	1387	1388	.
B-cv-bin-abs	1389	1390	0
O	1391	1392	(
B-cv-bin-percent	1392	1393	0
I-cv-bin-percent	1393	1394	%
O	1394	1395	)
O	1395	1396	,
O	1397	1399	RD
O	1400	1401	0
O	1401	1402	.
O	1402	1403	3
O	1403	1404	(
O	1404	1405	-
O	1406	1407	0
O	1407	1408	.
O	1408	1409	3
O	1409	1410	,
O	1410	1411	0
O	1411	1412	.
O	1412	1413	8
O	1413	1414	)
O	1414	1415	]
O	1415	1416	,
O	1417	1420	and
B-outcome	1421	1427	tissue
I-outcome	1428	1441	infiltrations
O	1442	1443	[
B-iv-bin-abs	1443	1444	4
O	1445	1446	(
B-iv-bin-percent	1446	1447	1
I-iv-bin-percent	1447	1448	.
I-iv-bin-percent	1448	1449	1
I-iv-bin-percent	1449	1450	%
O	1450	1451	)
O	1452	1454	vs
O	1454	1455	.
B-cv-bin-abs	1456	1457	1
O	1458	1459	(
B-cv-bin-percent	1459	1460	0
I-cv-bin-percent	1460	1461	.
I-cv-bin-percent	1461	1462	3
I-cv-bin-percent	1462	1463	%
O	1463	1464	)
O	1464	1465	,
O	1466	1468	RD
O	1469	1470	0
O	1470	1471	.
O	1471	1472	8
O	1472	1473	(
O	1473	1474	-
O	1475	1476	0
O	1476	1477	.
O	1477	1478	4
O	1478	1479	,
O	1479	1480	2
O	1480	1481	.
O	1481	1482	1
O	1482	1483	)
O	1483	1484	]
O	1484	1485	.

O	1486	1493	Overall
O	1493	1494	,
B-iv-bin-percent	1495	1496	8
I-iv-bin-percent	1496	1497	.
I-iv-bin-percent	1497	1498	0
I-iv-bin-percent	1498	1499	%
O	1500	1501	(
B-iv-bin-abs	1501	1502	6
O	1502	1503	/
B-intervention-participants	1503	1505	75
O	1505	1506	)
O	1507	1510	and
B-cv-bin-percent	1511	1512	7
I-cv-bin-percent	1512	1513	.
I-cv-bin-percent	1513	1514	7
I-cv-bin-percent	1514	1515	%
O	1516	1517	(
B-cv-bin-abs	1517	1518	5
O	1518	1519	/
B-control-participants	1519	1521	65
O	1521	1522	)
O	1523	1525	of
O	1526	1534	patients
O	1535	1538	had
O	1539	1541	at
O	1542	1547	least
O	1548	1551	one
O	1552	1554	of
O	1555	1560	these
B-outcome	1561	1574	complications
O	1575	1577	in
O	1578	1581	the
O	1582	1592	peripheral
O	1593	1596	and
O	1597	1604	central
O	1605	1611	access
O	1612	1616	arms
O	1617	1629	respectively
O	1630	1631	[
O	1631	1633	RD
O	1634	1635	-
O	1636	1637	0
O	1637	1638	.
O	1638	1639	9
O	1639	1640	(
O	1640	1641	-
O	1642	1643	9
O	1643	1644	.
O	1644	1645	4
O	1645	1646	,
O	1646	1647	7
O	1647	1648	.
O	1648	1649	6
O	1649	1650	)
O	1650	1651	]
O	1651	1652	.

O	1653	1656	The
O	1657	1662	study
O	1663	1666	was
O	1667	1677	terminated
O	1678	1683	early
O	1684	1687	due
O	1688	1690	to
O	1691	1695	slow
O	1696	1703	accrual
O	1703	1704	.

O	1705	1710	While
O	1711	1718	meeting
O	1719	1722	its
O	1723	1724	a
O	1725	1731	priori
O	1732	1743	feasibility
O	1744	1752	criteria
O	1753	1756	for
O	1757	1764	patient
O	1765	1775	engagement
O	1775	1776	,
O	1777	1780	the
O	1781	1785	slow
O	1786	1793	accrual
O	1794	1799	means
O	1800	1804	that
O	1805	1815	conducting
O	1816	1817	a
O	1818	1823	large
O	1824	1833	pragmatic
O	1834	1839	trial
O	1840	1845	would
O	1846	1853	require
O	1854	1864	overcoming
O	1865	1868	the
O	1869	1877	barriers
O	1878	1880	to
O	1881	1890	physician
O	1891	1902	recruitment
O	1902	1903	.

O	1904	1915	NCT02688998
O	1915	1916	.
